Needham & Company
-
Needham Reiterates Buy Rating on Revolution (RVMD)
-
Needham Reiterates Buy Rating on Revolution (RVMD)
-
Revolution (RVMD) PT Lowered to $61 at Needham
-
Revolution (RVMD) PT Raised to $62 at Needham
-
Revolution (RVMD) PT Raised to $46 at Needham
-
Revolution Medicines to Participate in Upcoming Investor Conferences
-
Revolution Medicines to Participate in 22nd Annual Needham Healthcare Conference

